Correlation between CXCR3 immunoreactivity and clinicopathological parameters
| Variable | No of patients (%) | p Value | |
|---|---|---|---|
| CXCR3− | CXCR3+ | ||
| MW, Mann–Whitney U test; KW, Kruskal–Wallis test. Trend χ2: χ2 test for linear trend. | |||
| Tumour thickness (mm) | 0.003 (MW)(⩽1, >1) | ||
| ⩽1 | 33 (84.6) | 6 (15.4) | 0.015 (MW)(⩽1, (1.01–4)) |
| 1.01–4 | 22 (59.5) | 15 (40.5) | 0.001 (MW)(⩽1, >4) |
| >4 | 1 (16.7) | 5 (83.3) | |
| Ulceration | 0.448 (MW) | ||
| No | 47 (70.1) | 20 (29.9) | |
| Yes | 9 (60) | 6 (40) | |
| Growth phase | 0.096 (MW) | ||
| Radial | 26 (78.8) | 7 (21.2) | |
| Vertical | 30 (61.2) | 19 (38.8) | |
| Recurrence | 0.425 (MW) | ||
| No | 49 (70) | 21 (30) | |
| Yes | 7 (58.3) | 5 (41.7) | |
| Lymph node metastasis | 0.206 (MW) | ||
| No | 44 (72.1) | 17 (27.9) | |
| Yes | 12 (57.1) | 9 (42.9) | |
| Distant metastasis | 0.048 (MW) | ||
| No | 49 (73.1) | 18 (26.9) | |
| Yes | 7 (46.7) | 8 (53.3) | |
| 5-year survival | 0.295 (MW) | ||
| Yes | 50 (70.4) | 21 (29.6) | |
| No | 6 (54.5) | 5 (45.5) | |
| Sex | 0.765 (MW) | ||
| Female | 30 (69.8) | 13 (30.2) | |
| Male | 26 (66.7) | 13 (33.3) | |
| Location | 0.533 (KW) | ||
| Extremities | 21 (61.8) | 13 (38.2) | |
| Trunk | 25 (71.4) | 10 (28.6) | |
| Head or neck | 10 (76.9) | 3 (23.1) | |
| Lymphocytic infiltration | 0.040 (Trend χ2) | ||
| Dense | 18 (81.8) | 4 (18.2) | |
| Ciscontinuous | 27 (69.2) | 12 (30.8) | |
| Absent | 11 (52.4) | 10 (47.6) | |